Biologit: AI Pharmacovigilance from MVP to Series A

Pharmacovigilance teams are required to monitor the scientific literature continuously for drug-safety signals, yet the volume of published medical research makes manual screening slow, expensive and error-prone. Biologit had a powerful AI engine capable of scanning more than 120 million medical abstracts, but an engine alone is not a product: it needed a secure, compliant SaaS platform that safety professionals could actually work in every day.

As an Enterprise Ireland-backed company at MVP stage, Biologit also needed to move quickly without compromising the standards that enterprise pharmaceutical buyers demand. That meant an interface designed for specialist scientific workflows, an architecture that could grow with the business, and a development team that could be assembled and led without distracting the founders from the science and the market.

Seditio designed the platform and its UI/UX from the ground up, translating complex literature-monitoring workflows into a clear, purposeful interface for pharmacovigilance specialists. The AI engine was integrated into a complete SaaS product, so that signal detection, screening and review sit within one coherent environment rather than a collection of disconnected tools.

On the engineering side, Seditio architected the platform on microservices capable of handling more than one million API calls per day, giving Biologit the headroom to serve enterprise workloads. Seditio also hired and continues to manage the remote development team, providing founder-led senior oversight so that delivery quality remains consistent as the product and team scale.

Because enterprise pharma buyers expect demonstrable security governance, ISO 27001 compliance was implemented across the platform — turning information security from a sales objection into a competitive strength.

Biologit progressed from an Enterprise Ireland-backed MVP to a Series A-funded company, with enterprise pilots underway with major pharmaceutical organisations. Along the way the platform achieved tenfold performance improvements between MVP and Series A, while the microservices architecture now sustains more than one million API calls daily.

With ISO 27001 compliance in place and a Seditio-managed development team behind the product, Biologit continues to scale its AI-driven literature monitoring for the global drug-safety market.